# Long-Term Renal Outcomes Following Left Renal Vein Ligation Versus Direct Splenorenal Shunt Ligation in Living Donor Liver Transplantation: A 10-Year Single-Center Study

**Authors:** Woo-Hyoung Kang, Deok-Bog Moon, Shin Hwang, Ki-Hun Kim, Chul-Soo Ahn, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Young-In Yoon, Byeong-Gon Na, Sang-Hoon Kim, Sung-Min Kim, Sung-Gyu Lee

PMC · DOI: 10.3389/ti.2026.16021 · Transplant International · 2026-02-18

## TL;DR

A 10-year study found that direct splenorenal shunt ligation may better protect kidney function compared to left renal vein ligation in liver transplant patients.

## Contribution

This study provides long-term renal outcome data comparing two surgical techniques in liver transplantation.

## Key findings

- Both surgical methods had similar survival rates but different long-term kidney impacts.
- Left renal vein ligation was linked to higher creatinine levels and dialysis needs.
- Direct shunt ligation may be preferable for patients at risk of kidney damage.

## Abstract

In living donor liver transplantation (LDLT), large splenorenal shunts (SRS) can divert portal inflow and negatively affect graft function due to portal steal syndrome. Direct SRS ligation (SRSL) and left renal vein ligation (LRVL) are used to prevent this complication; however, the long-term renal impact of LRVL remains unclear, particularly in recipients requiring nephrotoxic immunosuppression. We retrospectively analyzed adult LDLT recipients with large SRS (>1 cm) and normal baseline renal function who underwent SRSL (n = 120) or LRVL (n = 74). Patient and graft survival, serial renal function profiles, and tacrolimus trough levels were evaluated. Survival outcomes were comparable between the two groups. LRVL was more frequently performed in patients with higher preoperative Model for End-Stage Liver Disease (MELD) scores or increased transfusion requirements. During long-term follow-up, the LRVL group showed a more evident decline in renal function, with persistently higher serum creatinine levels, despite similar tacrolimus exposure. Four recipients in the LRVL group progressed to end-stage renal disease requiring dialysis within 10 years, whereas no dialysis cases occurred following SRSL. Although both strategies are clinically feasible, LRVL demonstrated a stronger association with progressive renal deterioration. These findings suggest that SRSL may be preferred in recipients with renal vulnerability to minimize cumulative renal burden.

Infographic summarizing a 10-year study comparing left renal vein ligation (LRVL) versus direct splenorenal shunt ligation (SRSL) in adult living donor liver transplant recipients. Diagram labels LRVL and SRSL shunt sites. Results state similar graft and patient survival; LRVL is preferred in difficult cases, but only LRVL had higher creatinine and dialysis rates. Conclusion notes both approaches are feasible, with SRSL possibly better for long-term renal protection.

## Full-text entities

- **Diseases:** DM (MESH:D009223), chronic kidney disease (MESH:D051436), decline in renal function (MESH:D060825), renal failure (MESH:D051437), bacterial peritonitis (MESH:D010538), diabetes (MESH:D003920), end-stage renal disease (MESH:D007676), hematuria (MESH:D006417), adhesions (MESH:D000267), hypertension (MESH:D006973), ALD (MESH:D000326), liver disease (MESH:D008107), portal hypertension (MESH:D006975), glomerulonephritis (MESH:D005921), -Stage Liver Disease (MESH:D058625), microvascular injury (MESH:D017566), autoimmune hepatitis (MESH:D019693), PSC (MESH:D015209), SRS (MESH:C562451), renal burden (MESH:D006030), proteinuria (MESH:D011507), portal steal syndrome (MESH:D013349), LDLT (MESH:D017093), venous congestion (MESH:D006940), Renal Function (MESH:D058186), Model (MESH:D004195), LRVL (MESH:D059228), alcoholic liver disease (MESH:D008108), bleeding (MESH:D006470), impaired renal perfusion (MESH:D007674)
- **Chemicals:** Cr (MESH:D002857), FK506 (MESH:D016559), mycophenolate mofetil (MESH:D009173), LDLT (-), Creatinine (MESH:D003404)
- **Species:** Homo sapiens (human, species) [taxon 9606], hepatitis C virus [taxon 11103], Hepatitis B virus (no rank) [taxon 10407]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12956752/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12956752/full.md

## References

12 references — full list in the complete paper: https://tomesphere.com/paper/PMC12956752/full.md

---
Source: https://tomesphere.com/paper/PMC12956752